Inactive Instrument

Analyst Reco. Arsanis Inc Nasdaq

Equities

US0428731097

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

B. Riley Downgrades X4 Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $1 From $3	Dec. 12	MT
B. Riley Trims X4 Pharmaceuticals' Price Target to $3 From $4, Keeps Buy Rating	23-08-30	MT
B. Riley Lifts X4 Pharmaceuticals' PT to $4 From $3, Notes 'Impressive' Follow-On Phase III WHIM Infections' Data; Keeps Buy Rating	23-05-18	MT
Stifel Adjusts Price Target on X4 Pharmaceuticals to $5 From $4, Maintains Buy Rating	23-05-17	MT
X4 Pharmaceuticals, Inc. Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Time of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome	23-05-16	CI
B. Riley Lowers X4 Pharmaceuticals' Price Target to $3 From $7 In Light of Recent Financing Resulting in Share Increase; Keeps Buy Rating	23-04-10	MT
Oppenheimer Adjusts X4 Pharmaceuticals Price Target to $4 From $5, Maintains Outperform Rating	23-03-24	MT
HC Wainwright Adjusts X4 Pharmaceuticals Price Target to $3 From $5, Maintains Buy Rating	23-03-22	MT
Cantor Fitzgerald Initiates X4 Pharmaceuticals With Overweight Rating, $3 Price Target	22-12-22	MT
Piper Sandler Starts X4 Pharmaceuticals at Overweight With $3 Price Target	22-12-12	MT
H.C. Wainwright Boosts Price Target on X4 Pharmaceuticals to $5 From $3.50, Reiterates Buy Rating	22-11-30	MT
Oppenheimer Adjusts X4 Pharmaceuticals Price Target to $5 From $8, Maintains Outperform Rating	22-08-08	MT
B. Riley Lowers X4 Pharmaceuticals' Price Target to $7 from $10 After Q1 Earnings Came Slightly Below Estimates, Keeps Buy Rating	22-05-19	MT
HC Wainwright Adjusts X4 Pharmaceuticals' Price Target to $8.50 from $11, Keeps Buy Rating	22-05-13	MT
Oppenheimer Adjusts X4 Pharmaceuticals' Price Target to $8 From $13, Maintains Outperform Rating	22-05-13	MT
Canaccord Genuity Adjusts Price Target on X4 Pharmaceuticals to $10 From $20, Reiterates Buy Rating	22-04-05	MT
Oppenheimer Adjusts X4 Pharmaceuticals' Price Target to $13 From $16, Maintains Outperform Rating	22-03-21	MT
B. Riley Lowers X4 Pharmaceuticals' PT to $10 from $15 on Increased Research, Development Spend Near Term, Lowered Drug Pricing; Keeps Buy Rating	21-12-16	MT
HC Wainwright Adjusts X4 Pharmaceuticals' Price Target to $11 From $21, Reiterates Buy Rating	21-12-14	MT
X4 PHARMACEUTICALS : Brookline Capital Starts X4 Pharmaceuticals at Buy With $21 Price Target	20-12-17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Arsanis Inc Nasdaq

Equities

US0428731097

Analyst Reco.

Filters